FI118653B - Menetelmä peptisen haavan riskin määrittämiseksi - Google Patents

Menetelmä peptisen haavan riskin määrittämiseksi Download PDF

Info

Publication number
FI118653B
FI118653B FI990992A FI990992A FI118653B FI 118653 B FI118653 B FI 118653B FI 990992 A FI990992 A FI 990992A FI 990992 A FI990992 A FI 990992A FI 118653 B FI118653 B FI 118653B
Authority
FI
Finland
Prior art keywords
gastrin
pepsinogen
risk
gastritis
concentration
Prior art date
Application number
FI990992A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI990992L (fi
FI990992A0 (fi
Inventor
Osmo Suovaniemi
Matti Haerkoenen
Pentti Sipponen
Erik Forsblom
Original Assignee
Biohit Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oyj filed Critical Biohit Oyj
Publication of FI990992A0 publication Critical patent/FI990992A0/fi
Priority to FI990992A priority Critical patent/FI118653B/fi
Priority to PCT/FI2000/000377 priority patent/WO2000067035A1/en
Priority to CN00808720.2A priority patent/CN100573152C/zh
Priority to EP00922684A priority patent/EP1173770B1/en
Priority to AT00922684T priority patent/ATE300053T1/de
Priority to JP2000615822A priority patent/JP4598959B2/ja
Priority to US09/959,551 priority patent/US6872543B1/en
Priority to AU42998/00A priority patent/AU4299800A/en
Priority to RU2001132335/15A priority patent/RU2225615C2/ru
Priority to PT00922684T priority patent/PT1173770E/pt
Priority to DE60021369T priority patent/DE60021369T2/de
Priority to ES00922684T priority patent/ES2241597T3/es
Priority to DK00922684T priority patent/DK1173770T3/da
Publication of FI990992L publication Critical patent/FI990992L/fi
Application granted granted Critical
Publication of FI118653B publication Critical patent/FI118653B/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seal Device For Vehicle (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI990992A 1999-04-30 1999-04-30 Menetelmä peptisen haavan riskin määrittämiseksi FI118653B (fi)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FI990992A FI118653B (fi) 1999-04-30 1999-04-30 Menetelmä peptisen haavan riskin määrittämiseksi
US09/959,551 US6872543B1 (en) 1999-04-30 2000-04-28 Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen I (PGI) and gastrin-17 in a serum sample
RU2001132335/15A RU2225615C2 (ru) 1999-04-30 2000-04-28 Способ дифференциации между наличием риска образования язвы желудка и язвы двенадцатиперстной кишки
EP00922684A EP1173770B1 (en) 1999-04-30 2000-04-28 Method for assessing the risk of peptic ulcer
AT00922684T ATE300053T1 (de) 1999-04-30 2000-04-28 Verfahren zur abschätzung eines magengeschwür- risikos
JP2000615822A JP4598959B2 (ja) 1999-04-30 2000-04-28 血清サンプル中のペプシノーゲンｉ（ｐｇｉ）とガストリン−１７の濃度の定量的測定の段階を含む、消化性潰瘍の危険性を評価する方法
PCT/FI2000/000377 WO2000067035A1 (en) 1999-04-30 2000-04-28 Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen i (pgi) and gastrin-17 in a serum sample
AU42998/00A AU4299800A (en) 1999-04-30 2000-04-28 Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen i (pgi) and gastrin-17 in a serum sample
CN00808720.2A CN100573152C (zh) 1999-04-30 2000-04-28 评估患消化性溃疡的危险度的方法,包括定量测定血清样品中胃蛋白酶原i(pgi)和胃泌素-17的浓度的步骤
PT00922684T PT1173770E (pt) 1999-04-30 2000-04-28 Metodo para estimar o risco de ulcera peptica
DE60021369T DE60021369T2 (de) 1999-04-30 2000-04-28 Verfahren zur Abschätzung eines Magengeschwürrisikos
ES00922684T ES2241597T3 (es) 1999-04-30 2000-04-28 Metodo para valorar el riesgo de ulcera peptica.
DK00922684T DK1173770T3 (da) 1999-04-30 2000-04-28 Fremgangsmåde til vurdering af risikoen for mavesår

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI990992 1999-04-30
FI990992A FI118653B (fi) 1999-04-30 1999-04-30 Menetelmä peptisen haavan riskin määrittämiseksi

Publications (3)

Publication Number Publication Date
FI990992A0 FI990992A0 (fi) 1999-04-30
FI990992L FI990992L (fi) 2000-10-31
FI118653B true FI118653B (fi) 2008-01-31

Family

ID=8554567

Family Applications (1)

Application Number Title Priority Date Filing Date
FI990992A FI118653B (fi) 1999-04-30 1999-04-30 Menetelmä peptisen haavan riskin määrittämiseksi

Country Status (13)

Country Link
US (1) US6872543B1 (enExample)
EP (1) EP1173770B1 (enExample)
JP (1) JP4598959B2 (enExample)
CN (1) CN100573152C (enExample)
AT (1) ATE300053T1 (enExample)
AU (1) AU4299800A (enExample)
DE (1) DE60021369T2 (enExample)
DK (1) DK1173770T3 (enExample)
ES (1) ES2241597T3 (enExample)
FI (1) FI118653B (enExample)
PT (1) PT1173770E (enExample)
RU (1) RU2225615C2 (enExample)
WO (1) WO2000067035A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010019L (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
AU2002252456A1 (en) * 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
SE0200974D0 (sv) * 2002-03-27 2002-03-27 Phagen Ab Screening method for gastritis
FI119571B (fi) * 2002-09-06 2008-12-31 Biohit Oyj Menetelmä esofagiitin tai Barrettin ruokatorven riskin osoittamiseksi yksilöllä
KR20050118690A (ko) * 2003-03-28 2005-12-19 애프톤 코포레이션 가스트린 호르몬 면역어세이
FI119572B (fi) * 2004-03-05 2008-12-31 Biohit Oyj Menetelmä vatsan limakalvon tilan ennustamiseksi
CA2561405C (en) * 2004-03-29 2014-01-21 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
DK1794586T3 (da) 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
WO2007007333A2 (en) * 2005-07-12 2007-01-18 Technion Research And Development Foundation Ltd. System and method for active detection of asymmetry in rotating structures
CN101910844A (zh) * 2007-10-26 2010-12-08 拜奥希特公司 用于诊断与萎缩性胃炎相联系的自身免疫性疾病和胃癌的方法和产品
RU2465597C1 (ru) * 2011-04-08 2012-10-27 Сергей Михайлович Котелевец Способ определения вероятности развития рака желудка
RU2582565C1 (ru) * 2015-03-06 2016-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации /ГБОУ ВПО ОрГМУ Минздрава России/ Способ дифференциальной диагностики язвы желудка и двенадцатиперстной кишки
CN104820096B (zh) * 2015-04-30 2017-04-19 必欧瀚生物技术（合肥）有限公司 一种判断早期胃癌风险检测用标志物的量的联合标准量及在筛查早期胃癌方面的应用
CN107271669A (zh) * 2016-09-23 2017-10-20 清华大学深圳研究生院 胃蛋白酶原、抗幽门螺杆菌抗体和胃泌素17检测方法及其试剂盒
CN107328938A (zh) * 2016-09-23 2017-11-07 清华大学深圳研究生院 胃蛋白酶原和抗幽门螺杆菌抗体检测方法及其试剂盒
JP6885581B2 (ja) * 2017-02-06 2021-06-16 学校法人東京歯科大学 ガストリン測定におけるカットオフ値の推定方法
EP3624841A4 (en) 2017-06-15 2021-01-27 Cancer Advances, Inc., COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
RU2677228C1 (ru) * 2017-12-08 2019-01-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Способ иммунодиагностики заболеваний гастродуоденальной зоны

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07304800A (ja) * 1994-05-06 1995-11-21 Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk ヒトペプシノゲンに対するモノクローナル抗体
FI97304C (fi) 1994-11-16 1996-11-25 Locus Genex Oy Menetelmä mahasyövän riskin seulonnaksi
JP2949474B2 (ja) * 1995-08-28 1999-09-13 隆久 古田 ペプシノーゲンｉ／ｉｉ比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法
JPH10148636A (ja) * 1996-11-15 1998-06-02 Takahisa Furuta ペプシノーゲン ｉ／ｉｉ 比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法

Also Published As

Publication number Publication date
EP1173770B1 (en) 2005-07-20
DE60021369D1 (de) 2005-08-25
FI990992L (fi) 2000-10-31
PT1173770E (pt) 2005-09-30
DE60021369T2 (de) 2006-05-24
DK1173770T3 (da) 2005-08-08
EP1173770A1 (en) 2002-01-23
ES2241597T3 (es) 2005-11-01
ATE300053T1 (de) 2005-08-15
RU2225615C2 (ru) 2004-03-10
CN1355888A (zh) 2002-06-26
CN100573152C (zh) 2009-12-23
JP4598959B2 (ja) 2010-12-15
FI990992A0 (fi) 1999-04-30
JP2002543433A (ja) 2002-12-17
WO2000067035A1 (en) 2000-11-09
US6872543B1 (en) 2005-03-29
AU4299800A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
FI118653B (fi) Menetelmä peptisen haavan riskin määrittämiseksi
EP0804737B1 (en) Method for screening the risk of gastric cancer
US7358062B2 (en) Method for diagnosing atrophic gastritis
Karnes Jr et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis
Stein et al. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function
Lähteenoja et al. Oral mucosal changes in
RU2462719C2 (ru) Диагностика септических осложнений
EP0329570A2 (en) Antigenic compositions containing fragments of Campylobacter pylori and methods for their production and use
Charrier et al. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two‐dimensional electrophoresis
Sieg et al. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces
Koehler et al. Diagnostic value of routine isoamylase assay of hyperamylasemic serum
Kurup et al. Antibody response to low-molecular-weight antigens of Aspergillus fumigatus in allergic bronchopulmonary aspergillosis
EP1552311B1 (en) Method for detecting a risk of acid related disease in an individual
Picarelli et al. Antiendomysial antibody detection in fecal supernatants: in vivo proof that small bowel mucosa is the site of antiendomysial antibody production
Sasaki et al. Elevated plasma thymosin-� 1 levels in lung cancer patients
WO2023281160A1 (en) Unified gastropanel in one microplate
Matsukura et al. Mucosal IgA antibody against helicobacter pylori in chronic gastritis and intestinal metaplasia detected by the tes‐tape method in resection specimens after gastrectomy for gastric cancer
Friis et al. Patients with coeliac disease have a characteristic gliadin antibody pattern
Gredal et al. The Lundh test and faecal elastase 1 determination in chronic pancreatitis: a comparative study
US20080162101A1 (en) Method for Predicting the State of the Gastric Mucosa
CA2414590A1 (en) Methods for monitoring treatment of helicobacter infection and for predicting the likelihood of successful eradication
Syrjänen Role of serological biomarker testing (GastroPanel®) in diagnosis of symptomatic dyspepsia and in screening of the risks of stomach cancer
Ventrucci Update on laboratory diagnosis and prognosis of acute pancreatitis
WO2003029826A1 (en) Method for detecting a cancer or precancerous condition
RU2224258C2 (ru) Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118653

Country of ref document: FI